---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055689"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:55:55.074611+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics Q1 net loss widens to $116.6M; cash $2.1B after $280M offering and $200M milestone

## Summary
- Net loss of $116.6M in Q1 2024 vs $53.1M in Q1 2023; R&D expenses fell 24% to $76.2M.
- Ended March with $2.1B cash; includes $280M February direct offering and $200M CASGEVY milestone from Vertex.
- CASGEVY now approved in 5 regions; over 25 ATCs activated globally, multiple patients have cells collected.
- Next-gen CAR T CTX112 (CD19) and CTX131 (CD70) trials ongoing; preliminary CTX112 data expected this year.
- New in vivo programs CTX340 (hypertension) and CTX450 (porphyria) enter IND-enabling studies; clinical trials targeted for H2 2025.

## SEC filing metadata
- accession: 0000950170-24-055689
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/0000950170-24-055689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/crsp-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055689
- JSON: https://secwatch.observer/filing/0000950170-24-055689.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055689.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, CRISPR Therapeutics AG announced its financial results for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/0000950170-24-055689-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.